Decoding TGR5: A comprehensive review of its impact on cerebral diseases

IF 9.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacological research Pub Date : 2025-02-21 DOI:10.1016/j.phrs.2025.107671
Zehan Zhang , Yifei Zhang , Hongye Peng, Qingqian Yu, Xiangdong Kang, Ying Liu, Yuxiao Zheng, Fafeng Cheng, Xueqian Wang, Feng Li
{"title":"Decoding TGR5: A comprehensive review of its impact on cerebral diseases","authors":"Zehan Zhang ,&nbsp;Yifei Zhang ,&nbsp;Hongye Peng,&nbsp;Qingqian Yu,&nbsp;Xiangdong Kang,&nbsp;Ying Liu,&nbsp;Yuxiao Zheng,&nbsp;Fafeng Cheng,&nbsp;Xueqian Wang,&nbsp;Feng Li","doi":"10.1016/j.phrs.2025.107671","DOIUrl":null,"url":null,"abstract":"<div><div>Currently, unraveling the enigmatic realm of drug targets for cerebral disorders poses a formidable challenge. Takeda G protein-coupled receptor 5 (TGR5), also known as G protein-coupled bile acid receptor 1, is a specific bile acid receptor. Widely distributed across various tissues, TGR5 orchestrates a myriad of biological functions encompassing inflammation, energy metabolism, fatty acid metabolism, immune responses, cellular proliferation, apoptosis, and beyond. Alongside its well-documented implications in liver diseases, obesity, type 2 diabetes, tumors, and cardiovascular diseases, a growing body of evidence accentuates the pivotal role of TGR5 in cerebral diseases. Thus, this comprehensive review aimed to scrutinize the current insights into the pathological mechanisms involving TGR5 in cerebral diseases, while contemplating its potential as a promising therapeutic target for cerebral diseases.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"213 ","pages":"Article 107671"},"PeriodicalIF":9.1000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661825000969","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, unraveling the enigmatic realm of drug targets for cerebral disorders poses a formidable challenge. Takeda G protein-coupled receptor 5 (TGR5), also known as G protein-coupled bile acid receptor 1, is a specific bile acid receptor. Widely distributed across various tissues, TGR5 orchestrates a myriad of biological functions encompassing inflammation, energy metabolism, fatty acid metabolism, immune responses, cellular proliferation, apoptosis, and beyond. Alongside its well-documented implications in liver diseases, obesity, type 2 diabetes, tumors, and cardiovascular diseases, a growing body of evidence accentuates the pivotal role of TGR5 in cerebral diseases. Thus, this comprehensive review aimed to scrutinize the current insights into the pathological mechanisms involving TGR5 in cerebral diseases, while contemplating its potential as a promising therapeutic target for cerebral diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
目前,揭开脑部疾病药物靶点的神秘面纱是一项艰巨的挑战。武田G蛋白偶联受体5(TGR5)又称G蛋白偶联胆汁酸受体1,是一种特异性胆汁酸受体。TGR5 广泛分布于各种组织,协调着炎症、能量代谢、脂肪酸代谢、免疫反应、细胞增殖、细胞凋亡等多种生物功能。TGR5在肝脏疾病、肥胖症、2型糖尿病、肿瘤和心血管疾病中的作用已得到充分证实,此外,越来越多的证据表明,TGR5在脑部疾病中发挥着关键作用。因此,这篇综合综述旨在仔细研究 TGR5 在脑部疾病中的病理机制,同时探讨其作为脑部疾病治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
期刊最新文献
Editorial Board Cleavage of the TrkB-FL Receptor During Epileptogenesis: Insights from a Kainic Acid-Induced Model of Epilepsy and Human Samples. Commentary on "Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study". Response to letter to the editor: Letter by Chen et al. Regarding Article, "Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study". CHPF2 as a novel biomarker and ponicidin as a potential therapeutic agent in hepatocellular carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1